Classical VEGF, Notch and Ang Signalling in Cancer Angiogenesis, Alternative Approaches and Future Directions (Review)

Overview

Journal Mol Med Rep

Specialty Molecular Biology

Date 2017 Aug 10

PMID 28791360

Citations 40

Authors

Nunzia Caporarello

Gabriella Lupo

Melania Olivieri

Martina Cristaldi

Maria Teresa Cambria

Mario Salmeri

Carmelina Daniela Anfuso

Affiliations

Soon will be listed here.

Abstract

Angiogenesis is the formation of new vessels starting from pre-existing vasculature. Tumour environment is characterized by 'aberrant angiogenesis', whose main features are tortuous and permeable blood vessels, heterogeneous both in their structure and in efficiency of perfusion and very different from normal vessels. Therapeutic strategies targeting the three pathways chiefly involved in tumour angiogenesis, VEGF, Notch and Ang signalling, have been identified to block the vascular supply to the tumour. However, phenomena of toxicity, development of primary and secondary resistance and hypoxia significantly blunted the effects of anti-angiogenic drugs in several tumour types. Thus, different strategies aimed to overcome these problems are imperative. The focus of the present review was some principal 'alternative' approaches to classic antiangiogenic therapies, including the cyclooxygenase-2 (COX-2) blockade, the use of oligonucleotide complementary to the miRNA to compete with the mRNA target (antimiRs) and the inhibition of matrix metalloproteinases (MMPs). The role of blood soluble VEGFA as a predictive biomarker during antiangiogenic therapy in gastric, ovarian and colorectal cancer was also examined.

Citing Articles

Functional gene signature offers a powerful tool for characterizing clinicopathological features and depicting tumor immune microenvironment of colorectal cancer.

Zhu Z, Li J, Fa Z, Xu X, Wang Y, Zhou J BMC Cancer. 2024; 24(1):1199.

PMID: 39342165 PMC: 11437988. DOI: 10.1186/s12885-024-12996-y.

The potential of vascular normalization for sensitization to radiotherapy.

Guo Z, Lei L, Zhang Z, Du M, Chen Z Heliyon. 2024; 10(12):e32598.

PMID: 38952362 PMC: 11215263. DOI: 10.1016/j.heliyon.2024.e32598.

LncRNA MALAT1 and Ischemic Stroke: Pathogenesis and Opportunities.

Khoshnam S, Moalemnia A, Anbiyaee O, Farzaneh M, Ghaderi S Mol Neurobiol. 2023; 61(7):4369-4380.

PMID: 38087169 DOI: 10.1007/s12035-023-03853-3.

Classical Angiogenic Signaling Pathways and Novel Anti-Angiogenic Strategies for Colorectal Cancer.

Cao M, Wang Y, Lu G, Qi H, Li P, Dai X Curr Issues Mol Biol. 2022; 44(10):4447-4471.

PMID: 36286020 PMC: 9601273. DOI: 10.3390/cimb44100305.

Tumor vessel normalization and immunotherapy in gastric cancer.

Yu X, He S, Shen J, Huang Q, Yang P, Huang L Ther Adv Med Oncol. 2022; 14:17588359221110176.

PMID: 35872968 PMC: 9297465. DOI: 10.1177/17588359221110176.

References

Cooper B, Ritchie J, Broghammer C, Coffin J, Sorosky J, Buller R . Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002; 8(10):3193-7. View

Salvati A, Pitek A, Monopoli M, Prapainop K, Bombelli F, Hristov D . Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013; 8(2):137-43. DOI: 10.1038/nnano.2012.237. View

Pan Y, Wu Q, Liu R, Shao M, Pi J, Zhao X . Inhibition effects of gold nanoparticles on proliferation and migration in hepatic carcinoma-conditioned HUVECs. Bioorg Med Chem Lett. 2013; 24(2):679-84. DOI: 10.1016/j.bmcl.2013.11.045. View

Jain R, Duda D, Clark J, Loeffler J . Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol. 2006; 3(1):24-40. DOI: 10.1038/ncponc0403. View

Li W, Zhao X, Du B, Li X, Liu S, Yang X . Gold Nanoparticle-Mediated Targeted Delivery of Recombinant Human Endostatin Normalizes Tumour Vasculature and Improves Cancer Therapy. Sci Rep. 2016; 6:30619. PMC: 4965746. DOI: 10.1038/srep30619. View

Scharpfenecker M, Fiedler U, Reiss Y, Augustin H . The Tie-2 ligand angiopoietin-2 destabilizes quiescent endothelium through an internal autocrine loop mechanism. J Cell Sci. 2005; 118(Pt 4):771-80. DOI: 10.1242/jcs.01653. View

Soker S, Takashima S, Miao H, Neufeld G, Klagsbrun M . Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell. 1998; 92(6):735-45. DOI: 10.1016/s0092-8674(00)81402-6. View

Lupo G, Motta C, Salmeri M, Spina-Purrello V, Alberghina M, Anfuso C . An in vitro retinoblastoma human triple culture model of angiogenesis: a modulatory effect of TGF-β. Cancer Lett. 2014; 354(1):181-8. DOI: 10.1016/j.canlet.2014.08.004. View

Ebos J, Lee C, Cruz-Munoz W, Bjarnason G, Christensen J, Kerbel R . Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3):232-9. PMC: 4540346. DOI: 10.1016/j.ccr.2009.01.021. View

10.

Mackey J, Ramos-Vazquez M, Lipatov O, McCarthy N, Krasnozhon D, Semiglazov V . Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. J Clin Oncol. 2014; 33(2):141-8. DOI: 10.1200/JCO.2014.57.1513. View

11.

Papadopoulos N, Martin J, Ruan Q, Rafique A, Rosconi M, Shi E . Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012; 15(2):171-85. PMC: 3338918. DOI: 10.1007/s10456-011-9249-6. View

12.

Raymond E, Dahan L, Raoul J, Bang Y, Borbath I, Lombard-Bohas C . Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364(6):501-13. DOI: 10.1056/NEJMoa1003825. View

13.

Lupo G, Caporarello N, Olivieri M, Cristaldi M, Motta C, Bramanti V . Anti-angiogenic Therapy in Cancer: Downsides and New Pivots for Precision Medicine. Front Pharmacol. 2017; 7:519. PMC: 5216034. DOI: 10.3389/fphar.2016.00519. View

14.

Penson R, Huang H, Wenzel L, Monk B, Stockman S, Long 3rd H . Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). Lancet Oncol. 2015; 16(3):301-11. PMC: 4479218. DOI: 10.1016/S1470-2045(15)70004-5. View

15.

Yao J, Wu X, Zhuang G, Kasman I, Vogt T, Phan V . Expression of a functional VEGFR-1 in tumor cells is a major determinant of anti-PlGF antibodies efficacy. Proc Natl Acad Sci U S A. 2011; 108(28):11590-5. PMC: 3136309. DOI: 10.1073/pnas.1109029108. View

16.

Tabernero J, Yoshino T, Lee Cohn A, Obermannova R, Bodoky G, Garcia-Carbonero R . Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised,.... Lancet Oncol. 2015; 16(5):499-508. DOI: 10.1016/S1470-2045(15)70127-0. View

17.

Jauhiainen S, Hakkinen S, Toivanen P, Heinonen S, Jyrkkanen H, Kansanen E . Vascular endothelial growth factor (VEGF)-D stimulates VEGF-A, stanniocalcin-1, and neuropilin-2 and has potent angiogenic effects. Arterioscler Thromb Vasc Biol. 2011; 31(7):1617-24. DOI: 10.1161/ATVBAHA.111.225961. View

18.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

19.

Banerjee I, De K, Mukherjee D, Dey G, Chattopadhyay S, Mukherjee M . Paclitaxel-loaded solid lipid nanoparticles modified with Tyr-3-octreotide for enhanced anti-angiogenic and anti-glioma therapy. Acta Biomater. 2016; 38:69-81. DOI: 10.1016/j.actbio.2016.04.026. View

20.

Duda D . Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. ISRN Cell Biol. 2013; 2012. PMC: 3856765. DOI: 10.5402/2012/587259. View